Peptide Reference

Aspartimide Formation and Why It Hides

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Aspartimide formation is a sequence-dependent side reaction in solid-phase synthesis of peptides containing aspartate. The backbone amide attacks the aspartate side chain to form a five-membered ring, which then opens to give products including isoaspartyl peptides of identical mass.

Key facts

Affects
Peptides containing aspartate
Sequence-dependent
Yes, Asp-Ala is a documented motif
Catalysed by
Acid or base
Mechanism
Adjacent amide attacks the side chain
Ring formed
Five-membered succinimide
Key product
Isoaspartyl peptide (same mass)
Also occurs in
Formulations, not only synthesis

What actually happens

The nitrogen of the peptide bond immediately following an aspartate residue attacks the carbonyl of that aspartate's side chain. That closes a five-membered ring: the aspartimide, a succinimide. Ruczyński and colleagues described it in the Journal of Peptide Science in 2008 as one of the most serious side reactions in solid-phase synthesis of aspartate-containing peptides, and both acid and base catalyse it.

Why the ring reopening is the real problem

The aspartimide is unstable and opens again, but it can open two ways. One restores the original aspartate linkage. The other produces an isoaspartyl peptide, where the chain now runs through the side-chain carboxyl instead of the backbone one: the same atoms in a different connectivity. Cao and colleagues reported in Biochemistry in 2023 that hydrolysis proceeds regioselectively above pH 7, so conditions determine which way it resolves.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

Why mass spectrometry cannot see it

An isoaspartyl peptide has the identical molecular formula and therefore the identical mass. Nothing was added and nothing was lost; a bond simply moved. A mass spectrum of a preparation substantially converted to isoaspartate looks exactly like a mass spectrum of the intended compound, which is why this impurity survives the check most certificates lead with.

Why it is sequence-dependent

The reaction needs the adjacent backbone nitrogen to reach the side-chain carbonyl, so what follows the aspartate governs how readily it happens. Small, unhindered residues make the approach easy. Ruczyński's work modelled the Asp-Ala motif specifically for this reason, and susceptibility varies substantially with the neighbouring residue.

Which compounds in this catalogue carry the motif

Both aspartate-containing peptides here. BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, which places an Asp-Ala pairing in the middle of the sequence. DSIP is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with the same Asp-Ala pairing. Neither is an unusual sequence, and neither product listing mentions the susceptibility.

That it is not only a synthesis problem

Cao and colleagues describe aspartimides as undesired side products in solid-phase synthesis and in pharmaceutical formulations. The chemistry does not stop when synthesis finishes. It can proceed slowly in a stored preparation, which makes it a stability consideration as well as a manufacturing one, and it is pH-sensitive in both settings.

Frequently asked questions

What is aspartimide formation?

A side reaction where the backbone amide following an aspartate attacks its side chain, forming a five-membered succinimide ring that can reopen incorrectly.

Why can't mass spectrometry detect the impurity?

The isoaspartyl product has the identical formula and mass. A bond moved; nothing was added or lost.

Which sequences are most at risk?

It is sequence-dependent, with small unhindered residues after the aspartate favouring it. Asp-Ala is a documented susceptible motif.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Peptide Reference articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.